MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

Phase 3
Completed
Conditions
Overactive Bladder
Interventions
First Posted Date
2007-01-22
Last Posted Date
2018-12-05
Lead Sponsor
Pfizer
Target Recruit Count
516
Registration Number
NCT00425100
Locations
🇺🇦

Pfizer Investigational Site, Zaporizhzhia, Ukraine

Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Biological: IMA-638
Other: placebo
First Posted Date
2007-01-22
Last Posted Date
2015-01-14
Lead Sponsor
Pfizer
Target Recruit Count
159
Registration Number
NCT00425061
Locations
🇺🇸

Allergy and Clinical Immunology, Pittsburgh, Pennsylvania, United States

🇺🇸

Allergy and Asthma Care Center of Southern California, Long Beach, California, United States

🇺🇸

Alabama Allergy & Asthma Clinic, Montgomery, Alabama, United States

and more 77 locations

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2007-01-19
Last Posted Date
2012-06-25
Lead Sponsor
Pfizer
Target Recruit Count
57
Registration Number
NCT00424632
Locations
🇧🇪

Pfizer Investigational Site, Leuven, Belgium

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
First Posted Date
2007-01-19
Last Posted Date
2007-02-13
Lead Sponsor
Pfizer
Target Recruit Count
320
Registration Number
NCT00424333
Locations
🇨🇦

Pfizer Investigational Site, Montreal, Quebec, Canada

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
First Posted Date
2007-01-19
Last Posted Date
2007-02-13
Lead Sponsor
Pfizer
Target Recruit Count
300
Registration Number
NCT00424411
Locations
🇨🇦

Pfizer Investigational Site, Montreal, Quebec, Canada

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
First Posted Date
2007-01-19
Last Posted Date
2007-02-13
Lead Sponsor
Pfizer
Target Recruit Count
320
Registration Number
NCT00424437
Locations
🇨🇦

Pfizer Investigational Site, Laval, Quebec, Canada

A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

Phase 2
Terminated
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2007-01-19
Last Posted Date
2014-09-25
Lead Sponsor
Pfizer
Target Recruit Count
70
Registration Number
NCT00424294
Locations
🇺🇸

Pfizer Investigational Site, Ogden, Utah, United States

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: placebo
First Posted Date
2007-01-17
Last Posted Date
2021-10-11
Lead Sponsor
Pfizer
Target Recruit Count
135
Registration Number
NCT00422461
Locations
🇺🇸

Orange County Research Center, Tustin, California, United States

🇺🇸

Riser Medical Associates, Picayune, Mississippi, United States

🇺🇸

Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States

and more 17 locations

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

Phase 3
Completed
Conditions
Osteoarthritis
Chronic Pain
Interventions
Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)
Drug: Placebo
First Posted Date
2007-01-11
Last Posted Date
2013-09-20
Lead Sponsor
Pfizer
Target Recruit Count
547
Registration Number
NCT00420992
Locations
🇺🇸

Advanced Biomedical Research of America, Las Vegas, Nevada, United States

🇺🇸

Community Research, Cincinnati, Ohio, United States

🇺🇸

International Clinical Research Institute, Inc, Overland Park, Kansas, United States

and more 76 locations

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Phase 1
Completed
Conditions
Lymphoma, Mantle-Cell
Interventions
First Posted Date
2007-01-09
Last Posted Date
2015-10-28
Lead Sponsor
Pfizer
Target Recruit Count
17
Registration Number
NCT00420056
Locations
🇺🇸

New York Presbyterian Hospital, New York, New York, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath